News

Learn more about the in-depth topics covered in the November 2024 CHE digital supplement of Dermatology Times.

Hawkes highlighted how second-generation TYK2 inhibitors improve upon earlier oral therapies with greater efficacy and selectivity.

Dermatology Times is looking back on the top stories in dermatology from the month of November.

Dermatology Times is recapping our top expert interviews from the month of November.

Data from Galderma's OLYMPIA 1 trial was recently published in JAMA Dermatology.

Learn more about the in-depth topics covered in the November 2024 AD and Vitiligo supplement of Dermatology Times.

Hawkes highlighted the intersection of oncology and dermatology, focusing on immune checkpoint inhibitors and their cutaneous adverse events.

A message of gratitude to the dermatology community for 45 years of collaboration, insights, and advancing care worldwide.

Learn more about the in-depth topics covered in the November 2024 print issue of Dermatology Times.

Patients treated with radiofrequency microneedling and Cysteamine cream saw significant improvement in melasma severity and skin texture.

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

This study demonstrates the use of AI-driven image analysis, leveraging the ScarletredVision app and machine learning, to diagnose and assess onychomycosis.

Plant-based compounds are being explored for their antioxidant and anti-inflammatory benefits in skin care.

Patients in 8 case studies saw notable improvements in post-traumatic, post-operative, and burn-related scars.

Older adults with higher genetic risk for HS show increased risks for coronary artery disease and diabetes, according to UK Biobank data.

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

Many dermatologists want to donate to charity while maximizing tax benefits, and certain tools can help achieve this.

Catch up on coverage from the 22nd annual Society of Dermatology Physician Associates Fall Dermatology Conference in Las Vegas, Nevada.

The JAK inhibitor was significantly superior in all safety and efficacy endpoints, when compared to other AA treatment options.

Researchers recommend limiting routine lipase tests to symptomatic patients or those with radiographic signs of pancreatic injury.

Certain factors may contribute to higher occurrences of non-melanoma skin cancer in these patients, according to a novel systemic review.

According to the company, comparative tests revealed PN-881 surpasses or matches the efficacy of current injectable IL-17 therapies.

Researchers found the TYK2 inhibitor deucravacitinib offers superior efficacy to apremilast and comparable outcomes to biologics.

Review insights from a premier dermatology event with expert sessions, hands-on insights, and networking to elevate clinical practice.

The LIBERO study confirmed brodalumab is effective in managing psoriasis in patients over 100 kg, showing comparable long-term benefits in patients under 100 kg.

Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.

These findings further suggest the implications of acne vulgaris treatment on the skin barrier.

Andrea Rosik, MS, PA-C, provides insights into managing challenging cases of atopic dermatitis.

Pediatric melanoma, though rare, is the deadliest skin cancer in children, with 300-500 US cases annually.